CL2018001408A1 - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer - Google Patents
Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncerInfo
- Publication number
- CL2018001408A1 CL2018001408A1 CL2018001408A CL2018001408A CL2018001408A1 CL 2018001408 A1 CL2018001408 A1 CL 2018001408A1 CL 2018001408 A CL2018001408 A CL 2018001408A CL 2018001408 A CL2018001408 A CL 2018001408A CL 2018001408 A1 CL2018001408 A1 CL 2018001408A1
- Authority
- CL
- Chile
- Prior art keywords
- ilo
- cancer
- treatment
- thiadiazole compounds
- methyl
- Prior art date
Links
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 FOR EXAMPLE Proteins 0.000 abstract 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 abstract 1
- 102000009127 Glutaminase Human genes 0.000 abstract 1
- 108010073324 Glutaminase Proteins 0.000 abstract 1
- 102100025960 Glutaminase kidney isoform, mitochondrial Human genes 0.000 abstract 1
- 101000856990 Homo sapiens Glutaminase kidney isoform, mitochondrial Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260787P | 2015-11-30 | 2015-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001408A1 true CL2018001408A1 (es) | 2018-10-12 |
Family
ID=57421876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001408A CL2018001408A1 (es) | 2015-11-30 | 2018-05-24 | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9938265B2 (enExample) |
| EP (1) | EP3383871B1 (enExample) |
| JP (1) | JP6873132B2 (enExample) |
| KR (1) | KR20180083412A (enExample) |
| CN (1) | CN108349967B (enExample) |
| AR (1) | AR106876A1 (enExample) |
| AU (1) | AU2016363719B2 (enExample) |
| BR (1) | BR112018010812A2 (enExample) |
| CA (1) | CA3005516C (enExample) |
| CL (1) | CL2018001408A1 (enExample) |
| CO (1) | CO2018006929A2 (enExample) |
| DK (1) | DK3383871T3 (enExample) |
| DO (1) | DOP2018000134A (enExample) |
| EA (1) | EA201891240A1 (enExample) |
| ES (1) | ES2759940T3 (enExample) |
| IL (1) | IL258644A (enExample) |
| MX (1) | MX2018006528A (enExample) |
| NI (1) | NI201800065A (enExample) |
| PE (1) | PE20181450A1 (enExample) |
| PH (1) | PH12018501132A1 (enExample) |
| SG (1) | SG11201803813UA (enExample) |
| SV (1) | SV2018005701A (enExample) |
| TN (1) | TN2018000126A1 (enExample) |
| TW (1) | TW201730188A (enExample) |
| WO (1) | WO2017093300A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| US10040789B2 (en) * | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) * | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| CN112888686B (zh) * | 2018-10-16 | 2022-04-19 | 南京明德新药研发有限公司 | 噻二唑衍生物及其作为gls1抑制剂的应用 |
| WO2025196446A1 (en) * | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU777824B2 (en) * | 1999-11-24 | 2004-11-04 | Merck Sharp & Dohme Corp. | Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors |
| US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| TWI287010B (en) * | 2003-06-12 | 2007-09-21 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| WO2006053342A2 (en) * | 2004-11-12 | 2006-05-18 | Osi Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
| PL2421826T3 (pl) * | 2009-04-20 | 2014-03-31 | Hoffmann La Roche | Pochodne proliny jako inhibitory katepsyn |
| RS59705B1 (sr) | 2011-11-21 | 2020-01-31 | Calithera Biosciences Inc | Heterociklični inhibitori glutaminaze |
| JP6275153B2 (ja) * | 2012-11-16 | 2018-02-07 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | ヘテロ環式グルタミナーゼ阻害剤 |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| EP3092235A2 (en) * | 2014-01-06 | 2016-11-16 | Rhizen Pharmaceuticals S.A. | Novel inhibitors of glutaminase |
| WO2015138902A1 (en) * | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10040789B2 (en) | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) * | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
-
2016
- 2016-11-29 US US15/363,018 patent/US9938265B2/en active Active
- 2016-11-29 TW TW105139312A patent/TW201730188A/zh unknown
- 2016-11-30 EA EA201891240A patent/EA201891240A1/ru unknown
- 2016-11-30 MX MX2018006528A patent/MX2018006528A/es unknown
- 2016-11-30 CN CN201680067261.2A patent/CN108349967B/zh active Active
- 2016-11-30 BR BR112018010812A patent/BR112018010812A2/pt not_active Application Discontinuation
- 2016-11-30 TN TNP/2018/000126A patent/TN2018000126A1/en unknown
- 2016-11-30 ES ES16802102T patent/ES2759940T3/es active Active
- 2016-11-30 DK DK16802102.0T patent/DK3383871T3/da active
- 2016-11-30 WO PCT/EP2016/079251 patent/WO2017093300A1/en not_active Ceased
- 2016-11-30 SG SG11201803813UA patent/SG11201803813UA/en unknown
- 2016-11-30 EP EP16802102.0A patent/EP3383871B1/en active Active
- 2016-11-30 AR ARP160103665A patent/AR106876A1/es unknown
- 2016-11-30 KR KR1020187017164A patent/KR20180083412A/ko not_active Withdrawn
- 2016-11-30 AU AU2016363719A patent/AU2016363719B2/en active Active
- 2016-11-30 CA CA3005516A patent/CA3005516C/en active Active
- 2016-11-30 JP JP2018526717A patent/JP6873132B2/ja active Active
- 2016-11-30 PE PE2018001021A patent/PE20181450A1/es unknown
-
2018
- 2018-04-11 IL IL258644A patent/IL258644A/en unknown
- 2018-05-24 CL CL2018001408A patent/CL2018001408A1/es unknown
- 2018-05-29 DO DO2018000134A patent/DOP2018000134A/es unknown
- 2018-05-29 SV SV2018005701A patent/SV2018005701A/es unknown
- 2018-05-29 NI NI201800065A patent/NI201800065A/es unknown
- 2018-05-29 PH PH12018501132A patent/PH12018501132A1/en unknown
- 2018-06-29 CO CONC2018/0006929A patent/CO2018006929A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2018000134A (es) | 2018-06-30 |
| PE20181450A1 (es) | 2018-09-12 |
| CA3005516A1 (en) | 2017-06-08 |
| JP6873132B2 (ja) | 2021-05-19 |
| CO2018006929A2 (es) | 2018-10-10 |
| CA3005516C (en) | 2024-04-16 |
| PH12018501132A1 (en) | 2019-01-21 |
| NI201800065A (es) | 2018-10-18 |
| AU2016363719A8 (en) | 2018-07-12 |
| SG11201803813UA (en) | 2018-06-28 |
| US20170152254A1 (en) | 2017-06-01 |
| AR106876A1 (es) | 2018-02-28 |
| EP3383871A1 (en) | 2018-10-10 |
| DK3383871T3 (da) | 2019-12-16 |
| ES2759940T8 (es) | 2020-05-20 |
| EP3383871B1 (en) | 2019-09-11 |
| EA201891240A1 (ru) | 2018-11-30 |
| SV2018005701A (es) | 2018-11-27 |
| CN108349967A (zh) | 2018-07-31 |
| IL258644A (en) | 2018-06-28 |
| MX2018006528A (es) | 2019-05-15 |
| AU2016363719B2 (en) | 2019-11-14 |
| KR20180083412A (ko) | 2018-07-20 |
| ES2759940T3 (es) | 2020-05-12 |
| JP2019501134A (ja) | 2019-01-17 |
| BR112018010812A2 (pt) | 2018-11-27 |
| TW201730188A (zh) | 2017-09-01 |
| US9938265B2 (en) | 2018-04-10 |
| WO2017093300A1 (en) | 2017-06-08 |
| AU2016363719A1 (en) | 2018-07-05 |
| CN108349967B (zh) | 2022-02-15 |
| TN2018000126A1 (en) | 2019-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2017002656A (es) | Compuestos que inhiben la proteína mcl-1. | |
| CL2017000240A1 (es) | Compuestos activos hacia bromodominios | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| CR20160099A (es) | Formulación de inhibidores de la syk | |
| CL2018001407A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| CL2017001209A1 (es) | Inhibidor de cinasa aurora a | |
| CL2015002698A1 (es) | Nuevos compuestos y composiciones para la inhibicion de fasn | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| CL2018001408A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| SV2018005713A (es) | Compuestos de isoindol | |
| CL2017002960A1 (es) | Compuesto para la profilaxis o el tratamiento de daño al órgano | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| AR106849A1 (es) | Compuestos de bis-piridazina y su uso en el tratamiento del cáncer | |
| MX2018001355A (es) | Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones. |